Is ELMD or ENOV more profitable?

Electromed has a net margin of 11.34% compared to Enovis' net margin of -49.92%. Electromed's return on equity of 15.71% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% Enovis -49.92% 10.32% 4.57%

Which has preferable earnings and valuation, ELMD or IRMD?

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $71.75M 5.29 $5.15M $1.17 39.16 iRadimed $83.81M 14.95 $22.48M $1.83 53.57

Is ELMD or IRMD more profitable?

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% iRadimed 27.36% 24.48% 21.25%

Which has higher valuation and earnings, CDRE or ELMD?

Cadre has higher revenue and earnings than Electromed. Cadre is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadre $610.31M 2.07 $44.14M $0.89 33.11 Electromed $71.75M 5.29 $5.15M $1.17 39.16

Is CDRE or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Cadre's net margin of 5.80%. Electromed's return on equity of 15.71% beat Cadre's return on equity. Company Net Margins Return on Equity Return on Assets Cadre 5.80% 12.39% 5.08% Electromed 11.34% 15.71% 13.37%

Electromed (ELMD) Competitors

$45.82 +1.88 (+4.28%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$45.93 +0.11 (+0.24%)

As of 07/9/2026 04:10 PM Eastern

Compare

ELMD vs. ENOV, INSP, BLFS, IRMD, and CDRE

Should you buy Electromed stock or one of its competitors? MarketBeat compares Electromed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Electromed include Enovis (ENOV), Inspire Medical Systems (INSP), BioLife Solutions (BLFS), iRadimed (IRMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.

How does Electromed compare to Enovis?

Electromed (NYSE:ELMD) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Electromed has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	5.29	$5.15M	$1.17	39.16
Enovis	$2.25B	0.64	-$1.18B	-$19.88	N/A

In the previous week, Enovis had 4 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Enovis and 0 mentions for Electromed. Electromed's average media sentiment score of 1.00 beat Enovis' score of -0.06 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Positive
Enovis	Neutral

40.8% of Electromed shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Electromed currently has a consensus target price of $37.50, indicating a potential downside of 18.16%. Enovis has a consensus target price of $41.71, indicating a potential upside of 65.72%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Enovis	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Electromed has a net margin of 11.34% compared to Enovis' net margin of -49.92%. Electromed's return on equity of 15.71% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Enovis	-49.92%	10.32%	4.57%

Electromed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Enovis has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Summary

Electromed beats Enovis on 11 of the 17 factors compared between the two stocks.

How does Electromed compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Inspire Medical Systems has higher revenue and earnings than Electromed. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	1.63	$145.42M	$4.49	11.48
Electromed	$71.75M	5.29	$5.15M	$1.17	39.16

Inspire Medical Systems has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Electromed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Inspire Medical Systems currently has a consensus price target of $81.05, suggesting a potential upside of 57.24%. Electromed has a consensus price target of $37.50, suggesting a potential downside of 18.16%. Given Inspire Medical Systems' higher probable upside, analysts clearly believe Inspire Medical Systems is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Inspire Medical Systems has a net margin of 14.33% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	14.33%	10.35%	8.81%
Electromed	11.34%	15.71%	13.37%

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Inspire Medical Systems had 4 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Inspire Medical Systems and 0 mentions for Electromed. Inspire Medical Systems' average media sentiment score of 1.00 equaled Electromed'saverage media sentiment score.

Company	Overall Sentiment
Inspire Medical Systems	Positive
Electromed	Positive

Summary

Inspire Medical Systems beats Electromed on 9 of the 15 factors compared between the two stocks.

How does Electromed compare to BioLife Solutions?

Electromed (NYSE:ELMD) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Electromed has a net margin of 11.34% compared to BioLife Solutions' net margin of -2.80%. Electromed's return on equity of 15.71% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
BioLife Solutions	-2.80%	1.81%	1.65%

Electromed has higher earnings, but lower revenue than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	5.29	$5.15M	$1.17	39.16
BioLife Solutions	$96.21M	14.34	-$4.59M	-$0.08	N/A

40.8% of Electromed shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Electromed's average media sentiment score of 1.00 beat BioLife Solutions' score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Positive
BioLife Solutions	Neutral

Electromed presently has a consensus target price of $37.50, indicating a potential downside of 18.16%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 13.35%. Given BioLife Solutions' higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

Summary

Electromed beats BioLife Solutions on 10 of the 15 factors compared between the two stocks.

How does Electromed compare to iRadimed?

Electromed (NYSE:ELMD) and iRadimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, iRadimed had 2 more articles in the media than Electromed. MarketBeat recorded 2 mentions for iRadimed and 0 mentions for Electromed. iRadimed's average media sentiment score of 1.03 beat Electromed's score of 1.00 indicating that iRadimed is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Positive
iRadimed	Positive

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	5.29	$5.15M	$1.17	39.16
iRadimed	$83.81M	14.95	$22.48M	$1.83	53.57

Electromed presently has a consensus price target of $37.50, suggesting a potential downside of 18.16%. iRadimed has a consensus price target of $120.00, suggesting a potential upside of 22.40%. Given iRadimed's higher possible upside, analysts clearly believe iRadimed is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
iRadimed	27.36%	24.48%	21.25%

40.8% of Electromed shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

iRadimed beats Electromed on 13 of the 15 factors compared between the two stocks.

How does Electromed compare to Cadre?

Cadre (NYSE:CDRE) and Electromed (NYSE:ELMD) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Electromed has a net margin of 11.34% compared to Cadre's net margin of 5.80%. Electromed's return on equity of 15.71% beat Cadre's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
Electromed	11.34%	15.71%	13.37%

44.0% of Cadre shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 30.1% of Cadre shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cadre presently has a consensus target price of $39.75, suggesting a potential upside of 34.91%. Electromed has a consensus target price of $37.50, suggesting a potential downside of 18.16%. Given Cadre's higher probable upside, equities analysts clearly believe Cadre is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

In the previous week, Cadre had 3 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Cadre and 0 mentions for Electromed. Electromed's average media sentiment score of 1.00 beat Cadre's score of 0.04 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadre	Neutral
Electromed	Positive

Cadre has higher revenue and earnings than Electromed. Cadre is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.07	$44.14M	$0.89	33.11
Electromed	$71.75M	5.29	$5.15M	$1.17	39.16

Cadre has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Electromed has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Electromed beats Cadre on 8 of the 15 factors compared between the two stocks.

Get Electromed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELMD vs. The Competition

Export

Metric	Electromed	Electromedical equipment Industry	Medical Sector	NYSE Exchange
Market Cap	$379.39M	$81.73M	$6.93B	$23.37B
Dividend Yield	N/A	N/A	2.68%	4.04%
P/E Ratio	61.09	10.19	27.37	31.18
Price / Sales	5.29	192.58	549.66	20.95
Price / Cash	41.36	41.36	48.45	24.85
Price / Book	8.98	5.39	11.02	4.77
Net Income	$5.15M	-$5.50M	$3.57B	$1.07B
7 Day Performance	0.86%	-1.35%	0.42%	-0.54%
1 Month Performance	23.24%	5.53%	6.55%	2.03%
1 Year Performance	128.99%	98.10%	29.66%	15.88%

Electromed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELMD Electromed	1.2304 of 5 stars	$45.82 +4.3%	$37.50 -18.2%	+123.4%	$379.39M	$71.75M	61.09	160	Positive News
ENOV Enovis	4.0273 of 5 stars	$25.52 -1.5%	$43.83 +71.8%	-29.1%	$1.47B	$2.25B	N/A	7,802	News Coverage Analyst Forecast Gap Up
INSP Inspire Medical Systems	4.5809 of 5 stars	$49.55 +0.2%	$81.05 +63.6%	-61.7%	$1.43B	$911.98M	11.05	1,333	Positive News
BLFS BioLife Solutions	2.3746 of 5 stars	$27.27 -1.9%	$32.00 +17.3%	+26.4%	$1.33B	$96.21M	N/A	440
IRMD iRadimed	2.5913 of 5 stars	$101.75 -0.5%	$120.00 +17.9%	+63.9%	$1.30B	$83.81M	55.54	110	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELMD) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Electromed (ELMD) Competitors